KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Total Debt (2016 - 2026)

Ionis Pharmaceuticals (IONS) has disclosed Total Debt for 18 consecutive years, with $432.5 million as the latest value for Q1 2026.

  • For Q1 2026, Total Debt changed N/A year-over-year to $432.5 million; the TTM value through Mar 2026 reached $432.5 million, changed N/A, while the annual FY2025 figure was $460.1 million, 786.04% up from the prior year.
  • Total Debt hit $432.5 million in Q1 2026 for Ionis Pharmaceuticals, down from $460.1 million in the prior quarter.
  • Across five years, Total Debt topped out at $630.9 million in Q3 2025 and bottomed at $8.8 million in Q1 2023.
  • Average Total Debt over 5 years is $186.2 million, with a median of $57.8 million recorded in 2022.
  • Year-over-year, Total Debt crashed 86.16% in 2023 and then soared 1318.83% in 2025.
  • Ionis Pharmaceuticals' Total Debt stood at $16.0 million in 2022, then skyrocketed by 439.46% to $86.2 million in 2023, then plummeted by 39.74% to $51.9 million in 2024, then surged by 786.04% to $460.1 million in 2025, then fell by 5.99% to $432.5 million in 2026.
  • According to Business Quant data, Total Debt over the past three periods came in at $432.5 million, $460.1 million, and $630.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.